CoChat
Sign Up
Cited by 356Retinal Diseases and TreatmentsRetinal and Macular SurgeryOcular Diseases and Behçet’s Syndrome

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

HORIZON: An Open-Label Extension Trial of Ranibizumab for Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

Singer, Michael A., Awh, Carl C., Sadda, SriniVas, Freeman, William R., Antoszyk, Andrew N., Wong, Pamela, Tuomi, Lisa·2012·Ophthalmology
DOI 10.1016/j.ophtha.2011.12.016
Open this paper in CoChat — free account

Abstract

Objective To evaluate the long-term safety and efficacy of multiple intravitreal ranibizumab injections (Lucentis, Genentech, Inc., South San Francisco, CA) administered at the investigator's discretion in patients with choroidal neovascularization secondary to age-related macular degeneration.Design An open-label, multicenter, extension study.Participants Patients who completed the controlled treatment phase of 1 of 3 prospective, randomized, 2-year clinical trials of ranibizumab were eligible for enrollment. Analyses were performed for 3 groups: (1) patients treated with ranibizumab in the initial study (ranibizumab treated-initial; n = 600); (2) patients randomized to control who crossed over to receive ranibizumab (ranibizumab treated-XO; n = 190); and (3) ranibizumab-naïve patients (ranibizumab untreated; n = 63).Methods Ranibizumab 0.5 mg was administered at the investigator's discretion. Adverse events (AEs) and Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) assessments were conducted at study visits every 3 to 6 months.Main outcome measures Incidence and severity of AEs.Results There was 1 occurrence of mild endophthalmitis per 3552 HORIZON injections in the ranibizumab treated-initial/ranibizumab treated-XO groups. There were no serious AE reports of lens damage, retinal tears, or rhegmatogenous retinal detachments in the study eyes. The proportion of patients with any single postdose intraocular pressure ≥30 mmHg was 9.2%, 6.6%, and 0%, and the proportion of patients with glaucoma was 3.2%, 4.2%, and 3.2% in the ranibizumab treated-initial, ranibizumab treated-XO, and ranibizumab untreated groups, respectively. Cataract AEs were less frequent in the ranibizumab untreated group: 6.3% versus 12.5% and 12.1% in the ranibizumab treated-initial and ranibizumab treated-XO groups, respectively. The proportion of patients with arterial thromboembolic events as defined by the Antiplatelet Trialists' Collaboration was 5.3% in the ranibizumab treated-initial and ranibizumab treated-XO groups, and 3.2% in the ranibizumab untreated group. At month 48 (2 years of HORIZON), the mean change in BCVA (ETDRS letters) relative to the initial study baseline was 2.0 in the ranibizumab treated-initial group versus -11.8 in the pooled ranibizumab treated-XO and ranibizumab untreated groups.Conclusions Multiple ranibizumab injections were well tolerated for ≥4 years. With less frequent follow-up leading to less treatment, there was an incremental decline of the visual acuity (VA) gains achieved with monthly treatment.Financial disclosure(s) Proprietary or commercial disclosure may be found after the references.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.ophtha.2011.12.016

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 14 references

Cited by

Sorted by citations

Items 201–300 of 356

Related

See all

Metadata

Authors
Singer, M. A., Awh, C. C., Sadda, S., Freeman, W. R., Antoszyk, A. N., Wong, P., & Tuomi, L.
Affiliations
  • Medical Center Ophthalmology Associates (US)
  • Tennessee Retina (US)
  • Doheny Eye Institute (US)
  • University of California San Diego (US)
  • Charlotte Eye Ear Nose & Throat Associates (US)
  • Genentech (US)
Corresponding author
Singer, Michael A.
ORCID
Venue
Ophthalmology
Publisher
Elsevier BV
Published
2012-06
Volume
119
Issue
6
Pages
1175-1183
ISSN
0161-6420 (ISSN-L)
DOI
10.1016/j.ophtha.2011.12.016
OpenAlex
W2011393181
Cited by
356
References
14
Citations by year
2026: 6 · 2025: 9 · 2024: 17 · 2023: 10 · 2022: 24 · 2021: 27 · 2020: 37 · 2019: 32 · 2018: 23 · 2017: 34 · 2016: 30 · 2015: 31 · 2014: 36 · 2013: 29 · 2012: 10
FWCI
31.69
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Ophthalmology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
  • Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
Keywords
ranibizumab, choroidal neovascularization, age-related macular degeneration, intravitreal injection, long-term safety, adverse events, endophthalmitis, intraocular pressure, glaucoma, cataract, visual acuity, anti-VEGF therapy, HORIZON trial, lens damage, retinal tears, retinal detachment
MeSH terms
Ranibizumab, Aged, Female, Follow-Up Studies, Humans, Macular Degeneration, Male, Visual Acuity, Treatment Outcome, Choroidal Neovascularization, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Intravitreal Injections, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review